Molecular Partners to Engage Investors at Upcoming Conferences
Molecular Partners AG, a dynamic biotech firm specializing in DARPin therapeutics, is gearing up for a series of important investor engagements. The company is excited to announce its participation in notable upcoming conferences designed to connect with potential investors and stakeholders.
Upcoming Events Overview
Among the key events, Molecular Partners will feature at the TD Cowen 44th Annual Health Care Conference in Boston, where CEO Patrick Amstutz and CMO Dr. Philippe Legenne will participate in a fireside chat. This event will take place from March 3 to 5, with Amstutz and Legenne's presentation scheduled for Monday, March 3 at 9:10 a.m. ET.
In addition to the conference participation, Molecular Partners will host a conference call to discuss its full-year financial results for 2024. This call is slated for March 7 at 8:00 a.m. ET, with the Annual Report to be released the day prior, on March 6.
Details for Conference Call Participation
Investors wishing to attend the financial results conference call can register using the following dial-in numbers approximately 10 minutes prior to the presentation:
Toll-Free Dial-in: 1-844-763-8274
International Dial-in: 1-412-717-9224
Switzerland Dial-in: 044-575-0267
A recording of the call will be accessible on the company's website following the event.
Leerink Partners Global Healthcare Conference
Following the TD Cowen conference, Molecular Partners will attend the Leerink Partners Global Healthcare Conference. Here, Amstutz and Legenne will again share insights during another fireside chat on March 10 at 10:40 a.m. ET.
About Molecular Partners AG
Founded in 2004, Molecular Partners AG focuses on creating innovative DARPin therapeutics aimed at addressing complex medical challenges that current drug modalities often cannot tackle. With a dedicated team, the company is developing its unique treatment strategies, particularly in oncology, while expanding its preclinical and clinical portfolios.
Its goal is to provide patients with groundbreaking solutions through both proprietary programs and collaborations with leading pharmaceutical partners. Molecular Partners strives to bridge the gap in patient care by offering innovative therapies designed to enhance treatment outcomes.
Contact Information
If you require further details or specific inquiries, please reach out to:
Seth Lewis, SVP Investor Relations & Strategy
Concord, Massachusetts, U.S.
Email: seth.lewis@molecularpartners.com
Phone: +1 781 420 2361
Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
Email: laura.jeanbart@molecularpartners.com
Phone: +41 44 575 19 35
Frequently Asked Questions
What is the focus of Molecular Partners AG?
Molecular Partners AG focuses on developing custom-built therapeutics known as DARPin therapeutics to address unmet medical needs.
When is Molecular Partners holding its financial results call?
The financial results call for 2024 will be on March 7 at 8:00 a.m. ET.
Where will Molecular Partners present its findings?
The company is participating in the TD Cowen Healthcare Conference and the Leerink Partners Global Healthcare Conference.
Who are the key speakers at the upcoming conferences?
CEO Patrick Amstutz and CMO Dr. Philippe Legenne will represent the company during the presentations.
How can investors access the conference call?
Investors can join the call by dialing the provided toll-free or international lines about 10 minutes before the call starts.